Moreover, in salivary gland cancer first phase-II trials on targeted therapies have been conducted and revealed that the use of anti-EGFR agents, such as cetuximab and gefitinib, failed to produce obvious response, although the majority of patients showed disease stabilisation (Glisson et al, 2005; Locati et al, 2009). The gene discussed is EGFR; the disease is salivary gland cancer.